Artelo Biosciences Achieves 40% Weight Loss in GLP-1 Combination Nonclinical Study

Combination data placing ART27.13 alongside semaglutide at roughly 40% weight reduction in a diet-induced obesity animal model signals a formulation and scale-up conversation that Artelo Biosciences is now actively positioning for, as the company filed a provisional patent covering ART27.13 for obesity and GLP-1 receptor agonist combination use.

The nonclinical findings, reported with Q3 2026 results, showed ART27.13 monotherapy achieving approximately 20% weight loss, comparable to semaglutide alone. The combination arm extended that effect to approximately 40%, while also improving oral glucose tolerance and increasing bone mineral density, outcomes not observed in any other treatment group in the model. For development teams tracking the obesity pipeline, the bone mineral density signal is notable given the known skeletal concerns associated with rapid weight loss regimens.

On the intellectual property side, Artelo received Notices of Allowance in both the U.S. and Japan for patent claims covering the intended commercial formulation of ART27.13. The U.S. patent, once issued, is expected to extend protection through 2041, providing a defined exclusivity window relevant to any prospective manufacturing or licensing discussions. The provisional patent filing on obesity and GLP-1 combination use adds a further layer ahead of anticipated partnership conversations the company referenced in its CEO commentary.

Beyond obesity, ART27.13 is also the subject of the investigator-led DREAM trial, a Phase 2 study now enrolling to evaluate whether daily oral ART27.13 can lower intraocular pressure in glaucoma or ocular hypertension patients. Running two Phase 2 programs concurrently across distinct indications places process development and supply planning under early scrutiny, particularly as the CAReS cancer-related anorexia interim data continues to support the asset's broader clinical profile.

Separately, ART26.12, the company's first-in-human FABP5 inhibitor, is scheduled to enter a Phase 1 multiple ascending dose study in Q4 2026, following single ascending dose results that demonstrated favorable safety, tolerability, and predictable pharmacokinetics. Nonclinical data presented at the IASP 2026 World Congress on Pain indicated pain relief comparable to naproxen with significantly less gastric tissue damage across chemotherapy-induced peripheral neuropathy, spinal cord injury, and osteoarthritis models.

R&D expenditure for the quarter ended September 30, 2026 was $0.8 million, down from $1.3 million in the same period of 2025, reflecting the current stage of the pipeline ahead of the anticipated MAD study initiation.

The MAD study start in Q4 2026 will serve as the near-term operational checkpoint for ART26.12, while the U.S. patent issuance timeline for ART27.13's commercial formulation will define the next IP milestone for teams monitoring the obesity combination space.

Source: Artelo Biosciences, Inc. via GlobeNewswire, November 12, 2026.